Abstract
Digital pathology offers powerful tools for biomarker discovery, analysis, and translation. Despite its advantages, the clinical adoption of digital pathology has been slow. A clinical and methodological validation is required for novel digital pathological biomarkers. Four steps are required to validate a novel pathological digital biomarker for clinical use: sample collection and processing, analytical validation, clinical validation, and clinical utility. The digital biomarkers and their diagnostic, monitoring, pharmacodynamic response, predictive, prognostic, safety, and risk assessment applications are discussed. Adopting pathological digital biomarkers can be used in conjunction with other diagnostic technologies to select the most appropriate patient treatment, thereby reducing patient suffering and healthcare costs.
Funder
National Research Foundation of Korea
Subject
Fluid Flow and Transfer Processes,Computer Science Applications,Process Chemistry and Technology,General Engineering,Instrumentation,General Materials Science
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献